Residual edema evaluation with ranibizumab 0.5 mg and 2.0 mg formulations for diabetic macular edema (REEF study)

Por Dhoot, D S, Pieramici, D J, Nasir, M, Castellarin, A A, Couvillion, S, See, R F, Steinle, N, Bennett, M, Rabena, M, Avery, R L
Publicado no Eye (Lond) (2015)

Common Variant in VEGFA and Response to Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration

Por Zhao, L., Grob, S., Avery, R., Kimura, A., Pieramici, D., Lee, J., Rabena, M., Ortiz, S., Quach, J., Cao, G., Luo, H., Zhang, M., Tornambe, P., Goldbaum, M., Ferreyra, H., Kozak, I., Zhang, K.
Publicado em 2013